nosed and 15,070 patients died of the disease. The incidence of adenocarcinoma of the esophagus is rising dramatically worldwide, whereas the incidence of squamous cell carcinoma (SqCC) is decreasing. 
carcinoma, the systemic nature of the disease attributes to the failure of surgery alone. Systemic chemotherapy, with or without radiotherapy, could lead to improved outcomes. Several authors have addressed the role of chemotherapy and radiation therapy, before and/or after surgery; however, their data have yielded confl icting results. The heterogenic patient populations, tumor biology (pathological response to therapy), and lack of a standard approach to esophagectomy may explain the discrepancies in results among institutions.
The majority of the studies published in the past three decades have included mostly patients with SqCC, and a distinction between the two subtypes has not always been made. However, it remains unclear as to whether histology should dictate the treatment approach. Extrapolating from these data when treating patients is acceptable until further data in adenocarcinoma are available. Enrollment in clinical trials should be encouraged.
In this article, we review the literature on treating LAEC as well as present our own treatment approach. Most of the trials reviewed excluded patients with SqCC of the cervical esophagus, and therefore interpretation of this review is limited to more distal tumors.
Treatment With Surgery Alone
Less than half of patients with esophageal cancer have resectable disease at presentation, based on staging positron emission tomography (PET) scans and esophageal ultrasonography. Surgical resection remains the standard treatment of early-stage disease. Endoscopic mucosal resection (EMR) is recommended for T1a disease if negative margins can be achieved. Upfront esophagectomy is recommended if EMR is not feasible in patients with positive margins following EMR or in patients with T1b disease.
Several clinical trials have used surgery alone as a control arm. For example, in the Radiation Therapy Oncology Group (RTOG) 8911 trial, patients who were randomized to surgery alone had a median survival of 1.3 years. 3 In surgery-only series, 5-year survival rates were less than 50% for patients with stage II or higher disease. [4] [5] [6] Therefore, it is currently recommended that patients with locally advanced disease (T2 or greater or node positive) receive neoadjuvant therapy (chemotherapy or chemoradiation).
Although there is great debate among surgeons regarding the technique of esophagectomy, median overall and disease-free survival rates have not been shown to differ statistically based on the surgical approach (extended transthoracic resection vs limited transhiatal resection). 4 In the 1980s, the overall survival rate after esophagectomy was 4%, with a surgical mortality rate of 25%. Currently, mortality rates after esophagectomy have decreased signifi cantly. Highervolume institutions have lower operative mortality rates for esophagectomy (more than a 12% absolute reduction in mortality compared with low-volume centers). 7 Referring patients with resectable esophageal cancer to a high-volume institution for surgical resection is crucial.
Preoperative Radiotherapy
Several randomized trials comparing neoadjuvant radiotherapy and surgery vs surgery alone in patients with LAEC have been reported. [8] [9] [10] [11] [12] [13] Investigators used different radiation doses and techniques. No statistically signifi cant difference was seen in overall survival with preoperative radiotherapy compared with surgery alone. These trials are summarized in Table 1 .
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Postoperative Radiotherapy
To improve local tumor recurrence, several randomized trials compared surgery alone with surgery followed by radiation therapy. Studies enrolled a heterogeneous population, including patients with 16 Investigators used higher doses of radiation with different fractionation. Radiation was delivered from 6 to 12 weeks following surgery. These trials had confl icting results, with three studies failing to demonstrate any survival benefi ts to adjuvant radiation 14, 15, 17 and one trial 16 showing a worse survival in patients who received radiation therapy. Another trial showed improvement in quality of life in the surgery-only arm compared with the adjuvant radiation arm. 15 A pooled analysis of the fi ve adjuvant radiation trials 18 showed no signifi cant difference in survival following adjuvant radiotherapy compared with surgery alone. Improvement in local tumor recurrence was reported in some of these trials but at the expense of toxicity. Preoperative radiotherapy was compared with postoperative radiotherapy in a small randomized trial; no difference in survival was detected between the two arms. 18 Patients receiving preoperative radiotherapy had a higher rate of morbidity.
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Preoperative Chemotherapy
Multiple randomized trials compared preoperative chemotherapy and surgery with surgery alone for the treatment of resectable esophageal cancer (Table  2) . 12, [19] [20] [21] [22] [23] [24] [25] [26] Of the seven earlier trials summarized, four showed no survival benefi t to neoadjuvant chemotherapy and three did show a survival benefi t with neoadjuvant chemotherapy compared with esophagectomy alone.
Larger, more recent studies have shown improved benefi ts for patient receiving neoadjuvant therapy. In the Medical Research Council (MRC) study, 19 802 patients with resectable esophageal cancer were randomly allocated to either 2 cycles of cisplatin and 5-fl uorouracil (5-FU) followed by surgical resection or resection alone. Postoperative complications were similar in both groups. Overall survival was prolonged in the chemotherapy group, with a median survival of 16.8 months vs 13.3 months in the surgery-only group. In the MAGIC trial, 20 503 patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus were randomly assigned to either perioperative chemotherapy or surgery alone. Chemotherapy consisted of 3 preoperative and 3 postoperative cycles of intravenous epirubicin, cisplatin, and continuous intravenous infusion of 5-FU. With a median followup of 4 years, the overall survival rate was significantly improved in the perioperative chemotherapy arm (36% vs 23%).
In an update of the MRC trial, 27 there were 655 deaths, 335 in the surgery arm and 320 in the chemotherapy arm. The survival benefi t has been maintained, with a hazard ratio (HR) of 0.84 (95% confidence interval [CI], 0.72-0.98; P = .03); in absolute terms, this represents a 5-year survival rate of 23.0% for chemotherapy and surgery compared with 17.1% for surgery alone. The treatment effect is consistent in both adenocarcinoma and SqCC.
Several pooled and meta-analyses addressed the role of neoadjuvant chemotherapy followed by sur- A meta-analysis published in 2002 included 11 randomized clinical trials (RTCs) comparing surgery alone with preoperative chemotherapy. 28 Again, no statistically signifi cant difference was reported in 3-year survival in patients who received preoperative chemotherapy compared with those who underwent upfront surgical resection. Two additional meta-analyses demonstrated survival benefi ts for preoperative chemotherapy; the fi rst was a Cochrane Review, which pooled 11 RCTs. A statistically signifi cant difference in survival favoring preoperative chemotherapy was detected only at 5 years. 29 An updated meta-analysis 30 comparing survival after neoadjuvant chemotherapy or surgery alone in 9 RTCs (total of 1,981 patients) for resectable esophageal cancer found strong evidence of a survival benefi t to neoadjuvant chemotherapy over surgery alone; there was a pooled HR of 0.87 (0.79-0.96; P = .005), which corresponded to an absolute survival difference at 2 years of 5.1%.
Postoperative Chemotherapy
A small number of randomized trials evaluated postoperative chemotherapy and surgery compared with surgery alone. Pouliquen et al 31 found no improvement in survival with postoperative chemotherapy (cisplatin/5-FU) in patients with SqCC. The duration of dysphagia was similar for both groups as well.
Another randomized trial conducted in Japan compared surgery alone vs surgery followed by adjuvant cisplatin/5-FU in 242 patients with SqCC. 32 The disease-free survival rate at 5 years favored the adjuvant therapy arm (55% vs 45%); however, the overall survival rate did not reach statistical signifi cance (61% vs 52%). The study included only patients with SqCC, the duration of adjuvant therapy was suboptimal, and about 25% of patients in the chemotherapy arms failed to receive the full course of adjuvant therapy.
Preoperative Chemoradiotherapy
The poor outcome associated with surgery alone and the high locoregional tumor recurrence rate with defi nitive chemoradiotherapy provided the rationale behind evaluating neoadjuvant chemoradiotherapy in patients with resectable esophageal cancer. At least 10 randomized trials compared neoadjuvant chemoradiotherapy followed by surgery with other modalities. These trials are summarized in Table 3. 12,33-41 The majority of patients included in these studies had SqCC, except in the more recent trials. Most trials did not have appropriate pre-enrollment staging. The Irish trial 33 and the Dutch trial 34 showed statistically signifi cant improvement in overall survival with combined preoperative chemoradiotherapy, but the Irish study was criticized for a lack of appropriate staging, premature closure, and an unusually poor survival rate in the surgery-alone arm.
The recently published phase III Dutch study 34 (the CROSS study) randomized patients with resectable esophageal cancer to receive surgery alone or weekly administration of carboplatin and paclitaxel for 5 weeks and concurrent radiotherapy followed by surgery. A total of 75% of patients had adenocarcinoma. R0 resection was achieved in 92% of patients in the chemoradiotherapy-surgery group vs 69% in the surgery group (P < .001). A pathological complete response (pCR) was achieved in 29% of patients who underwent resection after chemoradiotherapy. Postoperative complications were similar in both groups, as was in-hospital mortality. The median overall survival was 49.4 months in the chemoradiotherapysurgery group vs 24.0 months in the surgery group (HR, 0.657; 95% CI, 0.495-0.871; P = .003). Several meta-analyses have addressed the benefi t of trimodality therapy over surgery alone for esophageal cancer. The fi rst meta-analysis by Fiorica et al 42 pooled six RCTs comparing preoperative chemoradiation and surgery with surgery alone. Chemoradiotherapy followed by surgery signifi cantly decreased mortality (odds ratio [OR], 0.53; 95% CI, 0.31-0.93; P = .03). However, the risk of postoperative mortality was higher in the multimodality arm.
A second meta-analysis, by Urschel and Vasan, 43 pooled nine RCTs including 1,116 patients. A statistically signifi cant survival difference was found at 3 years in favor of preoperative chemoradiotherapy given concurrently (OR, 0.66; 95% CI, 0.47-0.92; P = .016). Neoadjuvant chemoradiotherapy was associated with a lower rate of resection but a higher rate of complete (R0) resection. A nonsignifi cant trend toward increased treatment mortality with neoadjuvant chemoradiotherapy was reported.
A third meta-analysis, by Gebski et al, 44 pooled 10 RCTs comparing neoadjuvant chemoradiotherapy vs surgery alone, with a total of 1,209 patients. A signifi cant survival benefi t was evident for preoperative chemoradiotherapy, with an HR of 0.81 (95% CI, 0.70-0.93; P = .002), corresponding to a 13% absolute difference in survival at 2 years. The results applied for SqCC demonstrated an HR of 0.84 (0.71-0.99; P = .04) and for adenocarcinoma, an HR of 0.75 (0.59-0.95; P = .02).
The most recent meta-analysis, by Sjoquist et al, 30 included 12 RCTs of neoadjuvant chemoradiotherapy vs surgery alone (1,854 patients). The updated analysis contained 4,188 patients, whereas the previous publication included 2,933 patients. This updated meta-analysis contained about 3,500 events, compared with about 2,230 in the previous meta-analysis (estimated 57% increase). The HR for all-cause mortality for neoadjuvant chemoradiotherapy was 0.78 (95% CI, 0.70-0.88; P < .0001); the HR for SqCC only was 0.80 (0.68-0.93; P = .004) and for adenocarcinoma only was 0.75 (0.59-0.95; P = .02). This analysis also compared neoadjuvant chemoradiotherapy with chemotherapy, where a survival benefi t was evident for neoadjuvant chemoradiotherapy but was not statistically signifi cant 0.88 (0.76-1.01; P = .07).
Neoadjuvant Chemotherapy vs Neoadjuvant Chemoradiotherapy
Two randomized trials compared neoadjuvant chemotherapy with neoadjuvant chemoradiotherapy; both trials included patients with adenocarcinoma, were closed early, and were underpowered to show a survival advantage. In the Australian trial, 45 75 patients were randomized to receive preoperative cisplatin and 5-FU or preoperative chemoradiotherapy with the same drugs with a lower dose of 5-FU. The pathological response rate was higher in the chemoradiotherapy arm (31% vs 8%; P = .01).
The median progression-free survival for the two groups was 14 and 26 months, also favoring the chemoradiotherapy arm (P = .37). The median overall survival was 29 months vs 32 months for the chemoradiotherapy arm, but it did not reach statistical signifi cance (P = .83).
In the Preoperative Chemotherapy or Radiochemotherapy in Esophago-gastric Adenocarcinoma Trial (POET), 46 126 patients with gastroesophageal junction adenocarcinoma were randomly assigned to receive chemotherapy alone (cisplatin/5-FU/leucovorin) for 15 weeks vs 12 weeks of the same regimen followed by low-dose radiotherapy concurrent with cisplatin and etoposide. The pCR rate was signifi cantly higher in the induction arm (16% vs 2%), with a nonsignifi cant trend toward a better 3-year survival rate as well (47% vs 28%; P = .07). A meta-analysis of the two trials 30 favored chemoradiotherapy, but it was not statistically signifi cant.
Institutional Experience
The majority of the previously mentioned studies found that pCR in the surgical specimen indicated a better overall outcome, which may make it tempting to intensify preoperative therapy by increasing the number and potency of chemotherapeutic agents and/or radiation therapy (including targeted therapy). However, we believe that profi ling genetic alterations in individual tumors combined with drug sensitivity assays is a better way to develop a tailored approach to treating patients in the neoadjuvant setting.
We have previously investigated (and published on 47, 48 ) the impact of response to neoadjuvant therapy in our own series of patients with esophageal cancer who underwent neoadjuvant therapy. We assessed the impact of pCR, partial pathological response (pPR), and no response (NR) in patients who underwent esophagectomy.
Among the 347 patients who underwent esophagectomy, 262 (75.5%) were treated with neoadjuvant therapy. A response to neoadjuvant therapy, including pCR (no residual tumor in the surgical specimen) or pPR (residual tumor in the surgical specimen with treatment effects compared with endoscopic ultrasonographic staging), was noted in 201 patients (76.7%). There were no differences in the response rates between patients with adenocarcinoma vs SqCC (P = .32). pCR was achieved in 106 patients (40.5%), pPR in 95 patients (36.3%), and NR in 61 patients (23.3%). A total of 92 patients (40.4%) with adenocarcinoma achieved pCR compared with 14 patients (41.2%) with SqCC (P = .56). Similar trends were noted in pPR (86 with adenocarcinoma [37 The 5-year overall and disease-free survival rates for the entire cohort of patients were 42.2% and 42.1%, with a median survival of 36 months (0-156 months) and a disease-free survival of 31 months (3-156 months), respectively. A decrease in overall and disease-free survival rates was noted with increasing tumor stage. When examining the impact of neoadjuvant therapy on overall survival, disease-free survival, tumor recurrence, and R1 resection, by pathological response, we demonstrated no difference in the 5-year overall survival rate among those receiving neoadjuvant therapy (39.4%) compared with patients who did not receive neoadjuvant therapy (46.3%; P = .057). However, the impact of pathological response predicted improvements in both overall and disease-free survival. Patients achieving a pCR had signifi cantly improved 5-year overall and disease-free survival rates (52%, 52%) compared with pPR (36%, 38%) or NR (22%, 19%; P < .0001, and P < .0001, respectively). The median survival in patients with pCR was 66 months (2-156 months), with pPR was 32 months (2-98 months), and with NR was 16 months (2-102 months).
Patients with NR fared worse in terms of 5-year overall and disease-free survival rates than did those who were treated with surgery alone (45.9% and 46.3%; P < .0001 and P < .0001, respectively). Additionally, patients achieving a pCR were more likely to have an R0 (100%) resection compared with a pPR (94.7%; P = .02), NR (88.5%; P = .0007), or surgery alone (91.8%; P = .002).
Adverse Effects and Surgical Complications
In the previously reviewed studies, adverse effects and surgical complications were inconsistently reported. Patients who underwent perioperative chemotherapy and/or radiation therapy experienced treatment-related toxicity more frequently compared with patients who underwent surgical resection alone. Data on toxicities and complications were not always reported in the meta-analyses either. With the newer surgical technique and the advances in supportive care, these complications are expected to decrease, especially if surgery is performed in a high-volume institution, where a multidisciplinary approach is followed in treating this patient population .
Discussion
Management of resectable esophageal cancer has undergone a major evolution over the past two decades. Several clinical trials have evaluated different modalities for managing locoregional cancer. However, large phase III trials with multiple arms comparing chemotherapy, radiation therapy, and surgery in different combinations are lacking. The clinical trials reviewed in this article included heterogeneous groups of patients with adenocarcinoma and SqCC, without uniform staging studies. Stage migration and changes in disease epidemiology impede the application of these trials to clinical practice. Comparing outcomes across such clinical trials is not recommended.
Patients with higher than T1 or node-positive disease who are surgical candidates should undergo some form of neoadjuvant therapy prior to surgery, based at least on the fi ndings of the recently published Dutch trial. 34 In this trial, patients who received neoadjuvant chemotherapy and radiation therapy had a median overall survival of 49.4 months, compared with 24 months in the surgery-alone group. Although controversial, esophagectomy remains an essential part of treatment and can lead to better overall survival, especially when performed in high-volume centers. The lack of a highly sensitive and/or specifi c test to confi rm complete response to neoadjuvant therapy, signifi cant morbidity of local disease recurrence, and improvement in surgical outcomes makes esophagectomy a necessity, even with SqCC, where defi nitive chemoradiotherapy is potentially curative. Large randomized trials comparing defi nitive chemotherapy and radiation therapy with surgical resection are lacking.
Based on the previously mentioned trials and meta-analyses for LAEC, we recommend concurrent chemoradiotherapy followed by surgery over surgery alone, based at least on the Dutch trial. 34 In Europe, the majority of patients with resectable esophageal cancer receive neoadjuvant chemotherapy, based on the MAGIC and the MRC trials; however, the results of these trials appear to contradict those of the US-based trials. 3, 25 The local tumor recurrence rate was unacceptably high in both the MAGIC and MRC trials, and the local failure rate appears to be lower with preoperative chemoradiotherapy. On the other hand, data on perioperative chemotherapy alone in SqCC are lacking.
The optimal neoadjuvant treatment regimen has not been established. The previously mentioned trials used different drugs, doses, and schedules of chemotherapy and radiation therapy. At our institution, we use platinum-based combination therapy rather than single-agent therapy concurrent with radiation therapy, based on our clinical pathway. Another option is weekly carboplatin/paclitaxel treatment (from the CROSS trial 34 ), especially in patients with renal insuffi ciency or in those who are not interested in a continuous infusion.
Data on adjuvant therapy after resection are lacking. For patients with completely resected nodepositive disease who have not received neoadjuvant therapy, we suggest postoperative adjuvant therapy with chemoradiotherapy, based on the INT-0016 trial. 49 Patients who have residual node-positive completely resected disease following neoadjuvant therapy (nonresponders) have had poor outcomes, and the potential benefi ts of adjuvant therapy in this setting are not clear. Our clinical pathway recommends close monitoring.
Conclusions
Several questions still need to be answered, as the majority of patients in the previously mentioned trials had squamous cell carcinoma, which is currently the less common histologic type in the United States, and patients did not have appropriate staging per current standards (ie, positron emission tomography scan or endoscopic ultrasonography). Furthermore, the optimal chemotherapy regimen has not been established; cisplatin has been the backbone of the previously used regimen, although newer regimens have shown promising results. Future trials in locally advanced esophageal cancer should include platinum-based chemoradiotherapy as a control arm, based on the CROSS study; secondary endpoints should include local disease control and quality of life.
Treatment decisions for individual patients should be based on comorbidities and the effects of neoadjuvant therapy on the patient's performance status and quality of life. Moving beyond TNM staging and incorporating a tumor's molecular biology could allow us to develop individualized therapy, which would potentially reduce treatment morbidity. Incorporating targeted therapy into neoadjuvant treatment based on tumor profi les will help identify patients who may be likely to benefi t from certain treatment modalities, which may improve outcomes in this disease.
